GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Klotho Neurosciences Inc (NAS:KLTO) » Definitions » Operating Margin %

KLTO (Klotho Neurosciences) Operating Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Klotho Neurosciences Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Klotho Neurosciences's Operating Income for the three months ended in Dec. 2024 was $-1.85 Mil. Klotho Neurosciences's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Klotho Neurosciences's Operating Margin % for the quarter that ended in Dec. 2024 was 0.00%.

The historical rank and industry rank for Klotho Neurosciences's Operating Margin % or its related term are showing as below:


KLTO's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -127.94
* Ranked among companies with meaningful Operating Margin % only.

Klotho Neurosciences's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Klotho Neurosciences's Operating Income for the three months ended in Dec. 2024 was $-1.85 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2024 was $-5.79 Mil.


Klotho Neurosciences Operating Margin % Historical Data

The historical data trend for Klotho Neurosciences's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Klotho Neurosciences Operating Margin % Chart

Klotho Neurosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Operating Margin %
- - - -

Klotho Neurosciences Quarterly Data
Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Klotho Neurosciences's Operating Margin %

For the Biotechnology subindustry, Klotho Neurosciences's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Klotho Neurosciences's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Klotho Neurosciences's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Klotho Neurosciences's Operating Margin % falls into.


;
;

Klotho Neurosciences Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Klotho Neurosciences's Operating Margin % for the fiscal year that ended in Dec. 2024 is calculated as

Operating Margin %=Operating Income (A: Dec. 2024 ) / Revenue (A: Dec. 2024 )
=-5.54 / 0
= %

Klotho Neurosciences's Operating Margin % for the quarter that ended in Dec. 2024 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=-1.852 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Klotho Neurosciences  (NAS:KLTO) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Klotho Neurosciences Operating Margin % Related Terms

Thank you for viewing the detailed overview of Klotho Neurosciences's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Klotho Neurosciences Business Description

Traded in Other Exchanges
N/A
Address
13576 Walnut Street, Suite A, Omaha, NE, USA, 68144
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.